Contents

Search


clioquinol (5-chloro-7-iodo-8-hydroxyquinoline)

Indications: - once used as anti-amoebic agent Adverse effects: -> subacute myelo-optico-neuropathy [SMON] (most likely subacute combined degeneration) probably related to vitamin B12 deficiency Mechanism of action: - halogenated 8-hydroxyquinoline [1] - chelates metal ions, binds Zn+2 & Cu+2 with greater affinity than Ca+2 & Mg+2 - lipophilic, freely crosses blood brain barrier - Clinical trials: - never emerged from phase II clinical trial for Alzheimer's disease 3/02

Interactions

drug interactions

General

antiparasitic agent chelating agent quinoline; leucoline; chinoleine; 1-benazazine; benzo[b]pyridine

Properties


Database Correlations

PUBCHEM cid=2788

References

  1. Rizk et al. J Pharmaceutical & Biomedical Analysis 27:813-20, 2002
  2. Melov S. '...and C is for Clioquinol' - the AbetaCs of Alzheimer's disease. Trends Neurosci. 2002 Mar;25(3):121-3; discussion 123-4. Review. PMID: 11852134
  3. Wang Y et al The anti-neurodegeneration drug clioquinol inhibits the aging- associated protein CLK-1. J Biol Chem. 2009 Jan 2;284(1):314-23. Epub 2008 Oct 15. PMID: 18927074

Component-of

clioquinol/cortisol clioquinol/cortisol/cortistatin